1. Home
  2. ETJ vs GYRE Comparison

ETJ vs GYRE Comparison

Compare ETJ & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

ETJ

Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

SELL

Current Price

$7.43

Market Cap

532.4M

Sector

Finance

ML Signal

SELL

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$4.33

Market Cap

625.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETJ
GYRE
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
532.4M
625.6M
IPO Year
2007
2004

Fundamental Metrics

Financial Performance
Metric
ETJ
GYRE
Price
$7.43
$4.33
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $18.67
AVG Volume (30 Days)
192.7K
★ 210.5K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $275,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$27.49
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.45
$3.97
52 Week High
$9.10
$9.14

Technical Indicators

Market Signals
Indicator
ETJ
GYRE
Relative Strength Index (RSI) 35.10 40.29
Support Level N/A $3.97
Resistance Level $8.53 $7.28
Average True Range (ATR) 0.14 0.42
MACD -0.02 0.04
Stochastic Oscillator 11.71 47.34

Price Performance

Historical Comparison
ETJ
GYRE

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: